Publications by authors named "Clara Padro Casas"
: The objective of this study was to provide real-world data on prognostic factors in children with severe eosinophilic asthma and to assess biomarkers of outcome. : Fifty-nine children (aged 6-17 years) were included in a prospective cohort attended in a Severe Asthma Unit of a tertiary care teaching hospital in Badalona (Barcelona, Spain) and visited at baseline and at 1-year follow-up. Study variables included asthma control using the Asthma Control Test (ACT), forced expiratory volume in one second (FEV), exacerbation episodes, fractional exhaled nitric oxide (FeNO), and inflammatory biomarkers (blood tests, sputum cells, immunoallergic tests, and levels of cytokines and effector cells in blood and sputum).
View Article and Find Full Text PDFA real-life ImmunoCAT study: impact of molecular diagnosis through ImmunoCAP ISAC 112 on immunotherapy prescription in pollen-polysensitized patients in Catalonia, Spain.
Allergol Immunopathol (Madr)
July 2024
Article Synopsis
- Molecular diagnosis in allergology, particularly using the ImmunoCAP ISAC 112 microarray, improves identification of specific allergens in patients, enhancing the understanding of their allergies.
- A study conducted in Catalonia assessed this method's impact on diagnosis and treatment (specifically immunotherapy) in young patients with allergic conditions, showing significant shifts in treatment plans.
- Results indicated that over half of the patients (51%) had changes in their immunotherapy prescriptions based on molecular diagnostic findings, suggesting this approach leads to better-targeted treatments.
A study was conducted in 98 adult patients diagnosed with severe eosinophilic asthma (73.5% women, mean age 47.2 years) and followed prospectively for 1 year.
View Article and Find Full Text PDFBackground: Convenient dosing is a key component of treatment adherence and thus efficacy and safety. Aqueous sublingual immunotherapy (SLIT) formulations can be administered with a dosing pump that delivers 200 µL of volume per actuation.
Objective: The objective of this study was to describe the use of Staloral 300 Rapid in its new dosing pump presentation and to evaluate the safety and satisfaction from both the patient and doctor.